NEW YORK – Global pharma company Servier has partnered with Celsius Therapeutics to identify new drug targets for colorectal cancer.
Celsius will use its single-cell genomics platform to analyze hundreds of samples from colorectal cancer patients. Under the agreement, Celsius will receive an undisclosed upfront payment and will be eligible for up to $700 million in milestone payments. Servier, which is headquartered in Suresnes, France, will receive an exclusive option to research, develop, and commercialize products directed to up to three of the targets.